½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1445738

PBM(Pharmacy Benefit Management) : ½ÃÀå Á¡À¯À² ºÐ¼®, »ê¾÷ µ¿Çâ ¹× Åë°è, ¼ºÀå ¿¹Ãø(2024-2029³â)

Pharmacy Benefit Management - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Mordor Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

PBM(Pharmacy Benefit Management) ½ÃÀå ±Ô¸ð´Â 2024³â 5,894¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. 2029³â±îÁö 7,753¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£(2024-2029³â) µ¿¾È 5.64%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾àÁ¦±Þ¿©°ü¸®- ½ÃÀå

ÁÖ¿ä ÇÏÀ̶óÀÌÆ®

  • COVID-19´Â ¾à¹° ÇýÅà °ü¸® ½ÃÀåÀÇ ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÃÆÀ¸¸ç, 2021³â1¿ùResearch in Social and Administrative Pharmacy¿¡ °ÔÀç µÈ ±â»ç¿¡ µû¸£¸é ´Ù¾çÇÑ ÀǾàÇ°, ƯÈ÷ ¸ÞÆ®Æ÷¸£¹Î ¹× ¿À¸ÞÇÁ¶óÁ¹°ú °°Àº ó¹æ¾à¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó º´¿øÀº Àη °ø±Þ°ú ¾à¹° °ü¸®¿¡ ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù. ¸ÞÆ®Æ÷¸£¹Î, ¿À¸ÞÇÁ¶óÁ¹°ú °°Àº ó¹æ¾à¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó º´¿øÀº ÀηÂ, ÀǾàÇ° °ø±Þ ¹× ¾à±¹ °ü¸® Ãø¸é¿¡¼­ ¾î·Á¿ò¿¡ Á÷¸éÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ´Ù¾çÇÑ ¾à±¹ °ü¸® ¼­ºñ½º¸¦ Á¦°øÇÏ´Â ±â¾÷µéÀº ¼öÀÍÀÌ Å©°Ô Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù.
  • ¿¹¸¦ µé¾î, 2021³â¿¬·Ê º¸°í¼­¿¡ µû¸£¸é Optum Inc.ÀÇ Optum RX(±¤¹üÀ§ÇÑ ¼Ò¸Å üÀÎ ¹× µ¶¸³ ¾à±¹ ³×Æ®¿öÅ©¸¦ °®Ãá Ç® ¼­ºñ½º ó¹æ¾à ÇýÅà Á¦°ø)ÀÇ ¼öÀÍÀº 2020³â874 ¾ï 9,800¸¸ ´Þ·¯¿¡¼­ 2021³â913 ¾ï 1, 400¸¸ ´Þ·¯·Î 4% Áõ°¡Çß½À´Ï´Ù. 400¸¸ ´Þ·¯·Î 4% Áõ°¡Çß½À´Ï´Ù. µû¶ó¼­ ÆÒµ¥¹Í ±â°£ µ¿¾È °üÂûµÈ ÀÌÁ¡À¸·Î ÀÎÇØ PBM ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀº Çظ¶´Ù Áõ°¡ ÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • ¾à¹° ±Þ¿© °ü¸®¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó Á¤È®µµ°¡ Çâ»óµÇ°í ¾à±¹ ¸ÅÀåÀÇ ¾ÈÀü¼º°ú È¿À²¼ºÀÌ Çâ»óµÉ »Ó¸¸ ¾Æ´Ï¶ó ȯÀÚÀÇ °Ç°­ °á°úµµ °³¼±µÉ °ÍÀÔ´Ï´Ù. ÀÌ´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ¿¹¸¦ µé¾î, 2022³â 3¿ù Rite AidÀÇ ¾à±¹ º¹¸®ÈÄ»ý °ü¸®ÀÚ(PBM) »ç¾÷ºÎÀÎ Elixir´Â PCMA(Pharmaceutical Care Management Association)ÀÇ È¸¿øÀ¸·Î °¡ÀÔÇß´Ù°í ¹àÇû½À´Ï´Ù. PCMA¿¡ ¿¤¸¯¼­°¡ Ãß°¡µÊ¿¡ µû¶ó ȯÀÚµéÀº ÇÕ¸®ÀûÀÎ °¡°ÝÀÇ Ã³¹æ¾àÀ» ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. µû¶ó¼­ Á¦¾à»ç, ¼Ò¸Å ¾à±¹ ¹× °Ç°­ º¸Çè»çµé »çÀÌ¿¡¼­ ÀǾàÇ° ÇýÅà °ü¸® ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ÀÖÀ¸¸ç, ÀÌ´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • Ä¡·áºñ, ÀÔ¿øºñ, °Ç°­°ËÁøºñ, ÀÔ¿øºñ µî ÀÇ·áºñ »ó½Â¿¡ µû¶ó º¸ÇèÀ» ÀÌ¿ëÇÏ´Â »ç¶÷µéÀÌ ´Ã°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ PBMÀº ÀÇ·á Á¦Ç°°ú ÀǾàÇ°À» °áÇÕÇÏ¿© ¿£µå Åõ ¿£µå ÀÇ·á ¼Ö·ç¼ÇÀ» Áö¿øÇÕ´Ï´Ù. À̸¦ ÅëÇØ º¸Çè»ç´Â ȯÀÚ¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ Á¤º¸¸¦ ¾òÀ» ¼ö ÀÖ°í, º¸Çè»ç´Â ȯÀÚ¿¡°Ô È¿°úÀûÀÎ ÇÁ·Î±×·¥À» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â ¶ÇÇÑ ÀǾàÇ° ÇýÅà °ü¸® ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÀÚ±ØÇÏ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ¶ÇÇÑ, Àü ¼¼°èÀûÀ¸·Î ÀÇ·á ÁöÃâÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀǾàÇ° Àç°í ¹× °ø±ÞÀ» ¸ð´ÏÅ͸µÇÏ°í ȯÀÚ¿¡°Ô Àú·ÅÇÑ ÀǾàÇ°À» Á¦°øÇϱâ À§ÇØ ±â¼úÀûÀ¸·Î Áøº¸µÈ ¼ÒÇÁÆ®¿þ¾î ¹× ¼Ö·ç¼ÇÀÇ µµÀÔÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀÌ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, ¸ÞµðÄÉ¾î ¸ÞµðÄÉÀÌµå ¼­ºñ½º ¼¾ÅÍ°¡ ¹ßÇ¥ÇÑ 2021³â µ¥ÀÌÅÍ¿¡ µû¸£¸é 2021³â ±¹¹Î ÀÇ·á ¼­ºñ½º´Â 2.7% Áõ°¡ÇÑ 4Á¶ 3,000¾ï ´Þ·¯(1Àδç 1¸¸ 2,914´Þ·¯)·Î GDPÀÇ 18.3%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °°Àº ÀÚ·á¿¡ µû¸£¸é 2021³â ¹Î°£ ÀǷẸÇè ÁöÃâÀº 5.8% Áõ°¡ÇÑ 1Á¶ 2,114¾ï ´Þ·¯, ó¹æ¾à ÁöÃâÀº 7.8% Áõ°¡ÇÑ 3,780¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù.
  • ¶ÇÇÑ, ÷´Ü ¼ÒÇÁÆ®¿þ¾î ¹× ¼Ö·ç¼Ç °³¹ß¿¡ ´ëÇÑ ±â¾÷ È°µ¿ÀÇ È°¼ºÈ­µµ ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, OptumÀº 2022³â 2¿ù º¹ÀâÇÑ Áõ»óÀ» °¡Áø ȯÀÚÀÇ Ä¡·á¸¦ °£¼ÒÈ­ÇÏ°í °í°¡ÀÇ Æ¯¼ö ÀǾàÇ° ºñ¿ëÀ» Àý°¨Çϱâ À§ÇØ Æ¯¼ö ¾à¹° °ü¸® ¼Ö·ç¼ÇÀÎ Optum Specialty FusionÀ» Ãâ½ÃÇß½À´Ï´Ù. ¿Í ÀÓ»ó °æÇèÀ» È°¿ëÇÏ¿© ȯÀÚ¿¡°Ô °¡Àå ÀûÀº ºñ¿ëÀ¸·Î °¡Àå È¿À²ÀûÀΠƯ¼öÄ¡·á¿¡ ´ëÇÑ ½Ç½Ã°£ ÅëÂû·ÂÀ» ÁöºÒÀÚ¿Í ÀÇ·áÁø¿¡°Ô Á¦°øÇÕ´Ï´Ù. µû¶ó¼­ ÀÇ·áºñ ÁöÃâ Áõ°¡, ó¹æ¾à ¼ö¿ä Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ÇØ´ç ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ¾à±¹ ÀÚµ¿È­ ½Ã½ºÅÛ µµÀÔ¿¡ ´ëÇÑ °ÅºÎ°¨°ú ±â¹Ð À¯Áö¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ÀýÂ÷´Â ¿¹Ãø ±â°£ µ¿¾È ÀǾàÇ° ÇýÅà °ü¸® ½ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

¾àÁ¦ ±Þ¿© °ü¸® ½ÃÀå µ¿Çâ

Àü¹® ¾à±¹ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È Å« ÆøÀÇ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»ó

  • Àü¹® ¾à±¹¿¡¼­´Â ´Ù¹ß¼º ¿Ü»ó, µÎºÎ ¿Ü»ó, ½ÉÇÑ È­»ó°ú °°Àº Èñ±ÍÇϰųª º¹ÀâÇÑ ÀÇÇÐÀû »óŸ¦ Ä¡·áÇϱâ À§ÇÑ ÀǾàÇ°À» Á¦°øÇÕ´Ï´Ù. À̵éÀº Ç¥ÁØÈ­ µÈ ÇÁ·Î¼¼½º¸¦ ÅëÇØ Æ¯¼öÇÑ Ãë±Þ, º¸°ü ¹× À¯Åë ¿ä±¸ »çÇ×ÀÌÀÖ´Â ÀǾàÇ°À» È¿À²ÀûÀ¸·Î °ø±ÞÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ÀǾàÇ°Àº ÀϹÝÀûÀ¸·Î º¹ÀâÇÑ Áúº´À» Ä¡·áÇÏ´Â µ¥ »ç¿ëµÇ´Â °í°¡ÀÇ Á¦Ç°ÀÔ´Ï´Ù. Àü¹® ¾à±¹ ºÎ¹®Àº ¸¸¼º Áúȯ ºÎ´ã Áõ°¡, ±â¾÷ È°µ¿ Áõ°¡·Î ÀÎÇÑ Ã³¹æ¾à ¼ö¿ä Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ÀǾàÇ° ÇýÅà °ü¸® ½ÃÀå¿¡¼­ »ó´çÇÑ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ȸ»çÀÇ Àü¹® ¾à±¹ ¼ÒÇÁÆ®¿þ¾î ¹× ¼Ö·ç¼Ç °³¹ß È°µ¿ÀÌ °è¼Ó Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È ºÎ¹®ÀÇ ¼ºÀåÀÌ °¡¼ÓÈ­ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 4¿ùSouthern Scripts´Â ¹Ì±¹ ±â¾÷°ú Á÷¿øÀÌ Æ¯¼ö ÀǾàÇ°ÀÇ ³ôÀº ºñ¿ëÀ» Àý°¨ ÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÈ »õ·Î¿î ¼Ö·ç¼Ç ÀÎ RxCompass¸¦ Ãâ½ÃÇß½À´Ï´Ù. ³×Æ®¿öÅ©¸¦ È°¿ëÇÏ¿© ȸ¿øµéÀÌ ´Ü°èº° ÇÁ·Î¼¼½º¸¦ ÅëÇØ °¡Àå ÇÕ¸®ÀûÀÎ °¡°ÝÀ¸·Î ÀÚ½ÅÀÇ ÇÊ¿ä¿¡ °¡Àå ÀûÇÕÇÑ Àü¹®ÀǾàÇ° °ü¸® ÇÁ·Î±×·¥À» ¼±ÅÃÇÒ ¼ö ÀÖ´Â ÃÖÃÊÀÇ È¸¿ø Á᫐ ¾à±¹ ³»ºñ°ÔÀÌ¼Ç ¼Ö·ç¼ÇÀ» °³¹ßÇß½À´Ï´Ù.
  • ¶ÇÇÑ 2022³â 3¿ù, VPLÀº ¾à»ç°¡ ¾à»ç¸¦ À§ÇØ ¾à»ç¸¦ À§ÇØ ¸¸µç ÀÓ»ó Áß½ÉÀÇ Àü¹® ¾à±¹ ¼ÒÇÁÆ®¿þ¾îÀÎ TrajectRx¸¦ Ãâ½ÃÇßÀ¸¸ç, TrajectRx´Â ¾à±¹¿¡¼­ ȯÀÚ Ä¡·á ½ÃÁ¡±îÁöÀÇ ÀÌÇà ÇÁ·Î¼¼½º¸¦ ¸íÈ®È÷ ÇÏ°í, ȯÀÚ Ä¡·áÀÇ ¿¬¼Ó¼ºÀ» ¿¬ÀåÇϸç, ÁöºÒÀÚ Áؼö ¹× ÀÎÁõ ±â°ü°ú Çù·ÂÇÏ¿© ÀǾàÇ°ÀÌ ºñ¿ë È¿À²ÀûÀÌ°í ¾ÈÀüÇÏ°Ô Á¦°øµÉ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù. ÁöºÒÀÚ Áؼö ¹× ÀÎÁõ ±â°ü°ú Çù·ÂÇÏ¿© ÀǾàÇ°ÀÌ ºñ¿ë È¿À²ÀûÀÌ°í ¾ÈÀüÇÏ°Ô Á¦°øµÉ ¼ö ÀÖµµ·Ï º¸ÀåÇÕ´Ï´Ù. µû¶ó¼­ ¾Õ¼­ ¾ð±ÞÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ Á¶»ç ´ë»ó ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì´Â ¿¹Ãø ±â°£ µ¿¾È »ó´çÇÑ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»ó

  • ºÏ¹Ì¿¡¼­´Â Åõ¾à ½Ç¼ö Áõ°¡, ¾à¹° ÇýÅà °ü¸® äÅà Áõ°¡, ÀÇ·áºñ Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È ¾à¹° ÇýÅà °ü¸® ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • 2022³â 7¿ù Oxford University Press¿¡ °ÔÀçµÈ ±â»ç¿¡ µû¸£¸é, ¹Ì±¹ÀÇ Àüü ó¹æ¾à ÁöÃâÀº Àü³âµµ 4%¿¡¼­ 2022³â 6%·Î Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µû¶ó¼­ ÀǾàÇ° ÁöÃâ Áõ°¡´Â ÀÌ Áö¿ªÀÇ Ã³¹æ¾à¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô´Ù´Â °ÍÀ» ÀǹÌÇϸç, ÀÌ´Â ¾à±¹ °ü¸® ½Ã½ºÅÛÀÇ Çʿ伺À» ÃËÁøÇÏ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ÀÌ Áö¿ª¿¡¼­ PBM ½Ã½ºÅÛÀ» äÅÃÇÏ´Â °æÇâÀÌ Áõ°¡ÇÏ°í ÀÖ´Â °ÍÀº ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 5¿ù ¹Ì±¹ »ó¿øÀÇ¿ø ¸¶¸®¾Æ ĵƮÀ£(¿ö½ÌÅÏÁÖ ¹ÎÁÖ´ç)°ú ô ±×·¡½½¸®(¾ÆÀÌ¿À¿ÍÁÖ ¹ÎÁÖ´ç)´Â ¿¬¹æ°Å·¡À§¿øȸ¿¡ ±ÇÇÑÀ» ºÎ¿©ÇÏ¿© ó¹æÀü ºñ¿ëÀ» Àý°¨ÇÏ´Â 2022³â ¾àÁ¦±Þ¿©°ü¸®ÀÚ Åõ¸í¼º¹ý(Drug Benefit Managers Transparency Act)À̶ó´Â ¹ý¾ÈÀ» Á¦ÃâÇß½À´Ï´Ù. ±×¸®°í ÁÖ ¹ý¹«Àå°üÀº ºÎ´çÇÏ°í ±â¸¸ÀûÀÎ PBM »óÇàÀ§¸¦ ÀúÁöÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ 2021³â 10¿ù¿¡´Â ¹Ì±¹ ¼Ò¸Å¾÷ü ¿ù¸¶Æ®¿Í ÄÚ½ºÆ®ÄÚ¸¦ Æ÷ÇÔÇÑ ¾à 40°³ ºñ¿µ¸® ¿¬ÇÕÀÌ °í¿ëÁÖ¿¡°Ô ¾à±¹ º¹¸®ÈÄ»ý °ü¸®(PBM) ¼­ºñ½º¸¦ Á¦°øÇÏ´Â »õ·Î¿î ȸ»ç¸¦ ¼³¸³Çß½À´Ï´Ù.
  • ¸¶Âù°¡Áö·Î 2021³â 10¿ù, Mark Cuban Cost Plus Drug Company PBC¿Í ¾à 40°³ ´ë±Ô¸ð °ø°ø ¹× ¹Î°£ °í¿ëÁÖÀÇ ºñ¿µ¸® ¿¬ÇÕÀÎ ±¸¸ÅÀÚ Business Group on Health´Â »õ·Î¿î ¾à±¹ º¹¸®ÈÄ»ý °ü¸® ȸ»ç PBMÀ» ¼³¸³Çß½À´Ï´Ù. ´Üü, Á¤ºÎ¸¦ ´ë½ÅÇÏ¿© ȯÀÚ°¡ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¾àÇ°À» ¼±ÅÃÇÏ°í, ÇØ´ç ¾àÇ°¿¡ ´ëÇÑ ºñ¿ë ÇÒÀÎÀ» Çù»óÇÏ°í, ¾à±¹¿¡ ´ëÇÑ ÁöºÒÀ» ó¸®ÇÕ´Ï´Ù. µû¶ó¼­ ¾à¹° ÇýÅà °ü¸® ½Ã½ºÅÛÀÇ Ã¤Åà Áõ°¡ ¹× ±â¾÷ È°µ¿ÀÇ ¼ºÀå°ú °°Àº ¿äÀÎÀ¸·Î ÀÎÇØ Á¶»ç ´ë»ó ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾àÁ¦ ±Þ¿© °ü¸® »ê¾÷ °³¿ä

¾à¹° ±Þ¿© °ü¸® ½ÃÀåÀº °æÀïÀÌ Ä¡¿­ÇÏ°í ¿©·¯ ¼¼°è ¹× ±¹Á¦ ½ÃÀå ±â¾÷ÀÌ Á¸ÀçÇÏ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¾÷µéÀº ÆÄÆ®³Ê½Ê, °è¾à, Çù¾÷, ½ÅÁ¦Ç° Ãâ½Ã, Áö¸®Àû È®Àå, ÇÕº´, ÀμöÇÕº´ µî ´Ù¾çÇÑ ¼ºÀå Àü·«À» ÅëÇØ ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­Çϱâ À§ÇØ ³ë·ÂÇÏ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¾÷À¸·Î´Â CVS Health, Optum, SS&C Technologies, Inc., Elixir Rx Solutions, LLC, Centene Corporation(Envolve Health) µîÀÌ ÀÖ½À´Ï´Ù.

±âŸ ÇýÅÃ

  • ¿¢¼¿ Çü½Ä ½ÃÀå ¿¹Ãø(ME) ½ÃÆ®
  • 3°³¿ù°£ ¾Ö³Î¸®½ºÆ® Áö¿ø

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç°ú ½ÃÀåÀÇ Á¤ÀÇ
  • Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ½ÃÀå °³¿ä
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • PorterÀÇ Five Forces ºÐ¼®
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ¹ÙÀ̾îÀÇ ±³¼··Â
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ´ëü Á¦Ç°ÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀïµµ

Á¦5Àå ½ÃÀå ¼¼ºÐÈ­

  • ¼­ºñ½ºº°
    • Àü¹® ¾à±¹
    • ÀǾàÇ° Á¦Á¦ °ü¸®
    • º¹¸®ÈÄ»ý Ç÷£ ¼³°è ¹× ÄÁ¼³ÆÃ
    • ±âŸ ¼­ºñ½º
  • ºñÁî´Ï½º ¸ðµ¨º°
    • Á¤ºÎ º¸°Ç ÇÁ·Î±×·¥
    • °í¿ëÁÖ ÁÖÃÖ ÇÁ·Î±×·¥
    • °Ç°­º¸Çè °ü¸®
  • ÃÖÁ¾»ç¿ëÀÚº°
    • ¾àÁ¦ ±ÞºÎ °ü¸® ±â±¸
    • Åë½Å ÆǸŠ¾à±¹
    • ¼Ò¸Å ¾à±¹
    • ±âŸ ÃÖÁ¾»ç¿ëÀÚ
  • Áö¿ª
    • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
    • À¯·´
      • µ¶ÀÏ
      • ¿µ±¹
      • ÇÁ¶û½º
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • È£ÁÖ
      • Çѱ¹
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
      • GCC
      • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
      • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¹Ì
      • ºê¶óÁú
      • ¾Æ¸£ÇîƼ³ª
      • ±âŸ ³²¹Ì

Á¦6Àå °æÀï ±¸µµ

  • ±â¾÷ °³¿ä
    • Optum, Inc.
    • Centene Corporation(Envolve Health)
    • CVS Health
    • SS&C Technologies, Inc.
    • Anthem, Inc.
    • Elixir Rx Solutions, LLC
    • Express Scripts Holding Company
    • Benecard Services, LLC
    • CaptureRx
    • Change Healthcare
    • Abarca Health
    • ProCare Rx
    • Cigna

Á¦7Àå ½ÃÀå ±âȸ¿Í ÇâÈÄ µ¿Çâ

LSH 24.03.19

The Pharmacy Benefit Management Market size is estimated at USD 589.40 billion in 2024, and is expected to reach USD 775.34 billion by 2029, growing at a CAGR of 5.64% during the forecast period (2024-2029).

Pharmacy Benefit Management - Market

Key Highlights

  • COVID-19 impacted the growth of the pharmacy benefit management market. According to an article published in Research in Social and Administrative Pharmacy, in January 2021, due to the rise in demand for different pharmaceuticals, especially prescription drugs such as metformin, omeprazole, and others, hospitals have faced difficulties in personnel, drug supply, and pharmaceutical care. Also, the companies providing a diversified array of pharmacy care services have reported a significant increase in their revenue.
  • For instance, as per the 2021 Annual Report, the revenue of Optum Inc. from Optum RX (a full-service prescription drug benefit provide) with a broad network of retail chains and independent pharmacies) was USD 91,314 million in 2021, with an increase of 4%, as compared to USD 87,498 million in 2020. Thus, the adoption of PBM solutions may increase over the years due to the benefits observed during the pandemic.
  • The rising inclination towards pharmacy benefits management increases the accuracy, improves the safety and efficiency of the pharmacy store as well as improves patient health outcomes. This is anticipated to fuel the market growth over the forecast period.
  • For instance, in March 2022, Elixir, the pharmacy benefit manager (PBM) division of Rite Aid, revealed its membership in the Pharmaceutical Care Management Association (PCMA). The addition of Elixir to PCMA boosts patients' access to affordable prescription drugs. Thus, the growing demand for pharmacy benefit management services among drug manufacturers, retail pharmacies, and health insurance providers is expected to fuel the market growth over the forecast period.
  • The increase in the number of persons utilizing insurance to deal with the rise in medical costs, such as paying for treatment, hospitalization, health check-up, and hospitalization charges. Additionally, PBM combines medical and pharmaceutical products to support end-to-end healthcare solutions that enable the insurers to have comprehensive information about the patients, which enables the insurers to offer patients effective programs. This is also expected to fuel the demand for pharmacy benefit management systems, hence bolstering market growth.
  • Furthermore, the rising health spending across the globe is expected to increase the adoption of technologically advanced software and solutions to monitor the inventory and supply of drugs as well as provide affordable medications to patients. This is anticipated to augment the market growth over the forecast period. For instance, according to the 2021 data published by the Centers for Medicare and Medicaid Services, the National Health Service increased by 2.7% to USD 4.3 trillion in 2021 (USD 12,914 per person), which accounted for 18.3% of GDP. In addition, as per the same source, private health insurance spending increased by 5.8% to USD 1,211.4 billion in 2021, and prescription drug spending increased by 7.8% to USD 378 billion in 2021.
  • Moreover, the rising company activities in developing advanced software and solutions are also contributing to market growth. For instance, in February 2022, Optum launched Optum Specialty Fusion, a specialty medication management solution, to simplify care for patients with complex conditions and lower the cost of expensive specialty drugs. Specialized Fusion offers payers and providers of healthcare real-time insight into the most efficient specialty treatments at the patient's lowest cost by utilizing Optum's data and clinical experience. Therefore, owing to the factors such as growing health expenditure and increasing demand for prescription drugs, the studied market is expected to grow over the forecast period. However, the reluctance to adopt pharmacy automation systems and stringent regulatory processes on confidentiality are likely to hinder the growth of the pharmacy benefit management market over the forecast period.

Pharmacy Benefit Management Market Trends

Specialty Pharmacy Segment is Expected to Witness Significant Growth Over the Forecast Period

  • Specialty pharmacies provide drugs to treat rare or complex medical conditions, such as multiple trauma, head injuries, severe burns, and others. They are designed to efficiently supply drugs with special handling, storage, and distribution requirements with standardized processes. These medications are usually high-cost products used to treat complex diseases. The specialty pharmacy segment is expected to witness significant growth in the pharmacy benefit management market over the forecast period owing to the factors such as the growing demand for prescription drugs owing to the rising burden of chronic diseases and the increasing company activities.
  • The growing company's activities in developing specialty pharmacy software and solutions are expected to increase segment growth over the forecast period. For instance, in April 2022, Southern Scripts launched RxCompass, a new solution designed to support United States companies and their employees in mitigating the high costs of specialty medications. Southern Scripts uses its PBM expertise and industry network to create the first member-centric pharmacy navigation solution that can lead members through a step-by-step process to choose the specialty drug management program that best addresses their unique needs at the most affordable price.
  • Also, in March 2022, VPL launched TrajectRx, a clinically minded specialty pharmacy software built for pharmacists by pharmacists.TrajectRx clarifies the fulfillment process from the pharmacy to the point of patient care and aids in extending the continuity of patient care, providing compliance with payors and accrediting authorities, and ensuring medications are delivered cost-effectively and securely. Therefore, owing to the aforementioned factors, the studied market is anticipated to grow over the forecast period.

North America is Expected to Have the Significant Market Share Over the Forecast Period

  • North America is anticipated to witness significant growth in the pharmacy benefit management market over the forecast period owing to the factors such as the increasing number of medication errors, increasing adoption of pharmacy benefit management, and rising healthcare expenditure.
  • According to an article published in Oxford University Press in July 2022, it has been observed that overall prescription drug spending was expected to increase from 4% in the previous year to 6% in 2022 in the United States. Thus, the increased drug spending indicates the high demand for prescription drugs in the region, which is anticipated to propel the need for pharmacy management systems, bolstering market growth.
  • The growing inclination towards adopting PBM systems in the region is the key factor driving the market growth. For instance, in May 2022, the United States Sens Maria Cantwell (D-Wash.) and Chuck Grassley (D-Iowa) introduced a bill, the Pharmacy Benefit Manager Transparency Act of 2022, to reduce prescription costs by empowering the Federal Trade Commission and state attorneys general to halt unfair and deceptive PBM business practices. Also, in October 2021, a nonprofit coalition of nearly 40 companies, including United States retailers Walmart and Costco, launched a new firm that would offer pharmacy benefit management (PBM) services for employers.
  • Similarly, in October 2021, Mark Cuban Cost Plus Drug Company PBC and the Purchaser Business Group on Health, a nonprofit coalition of nearly 40 large public and private employers, launched a new pharmacy-benefit management company. PBMs, on behalf of businesses, labor organizations, and governments, choose which medications patients have access to, negotiate discounts on the costs of those medications, and handle payments to pharmacies. Therefore, owing to the factors such as the rising adoption of pharmacy benefit management systems and growing company activities, the studied market is expected to grow over the forecast period.

Pharmacy Benefit Management Industry Overview

The pharmacy benefit management market is competitive, with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key companies in the market are CVS Health, Optum, SS&C Tecnologies, Inc., Elixir Rx Solutions, LLC, and Centene Corporation (Envolve Health), among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Inclination Towards Pharmacy Benefit Management System (PBMS)
    • 4.2.2 Increasing Health Expenditure
    • 4.2.3 Growing Demand for Prescription Products
  • 4.3 Market Restraints
    • 4.3.1 Reluctance To Adopt Pharmacy Automation Systems and Stringent Regulatory Procedures on Confidentiality
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Service
    • 5.1.1 Specialty Pharmacy
    • 5.1.2 Drug Formulatory Management
    • 5.1.3 Benefit Plan Design and Consultation
    • 5.1.4 Other Services
  • 5.2 By Business Model
    • 5.2.1 Government Health Programs
    • 5.2.2 Employer-Sponsored Programs
    • 5.2.3 Health Insurance Management
  • 5.3 By End-User
    • 5.3.1 Pharmacy Benefit Management Organization
    • 5.3.2 Mail Order Pharmacies
    • 5.3.3 Retail Pharmacies
    • 5.3.4 Other End-Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Optum, Inc.
    • 6.1.2 Centene Corporation (Envolve Health)
    • 6.1.3 CVS Health
    • 6.1.4 SS&C Technologies, Inc.
    • 6.1.5 Anthem, Inc.
    • 6.1.6 Elixir Rx Solutions, LLC
    • 6.1.7 Express Scripts Holding Company
    • 6.1.8 Benecard Services, LLC
    • 6.1.9 CaptureRx
    • 6.1.10 Change Healthcare
    • 6.1.11 Abarca Health
    • 6.1.12 ProCare Rx
    • 6.1.13 Cigna

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦